GeneDx

Name

GeneDx

Legal name

GeneDx, LLC

Website

https://genedx.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Clinical Genomics / Rare Disease Genetic Testing Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Clinical genetic testing
• Whole exome sequencing
• Whole genome sequencing
• Rare disease diagnostics
• Genomic data platform

Headquarters

HQ city

Stamford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical genetic testing services: Primary revenue from clinical exome and genome sequencing tests billed to commercial insurance, Medicaid, Medicare, TRICARE, institutional accounts, or self-pay; recognized across all major payors as in-network provider.
2. Biopharma data partnerships: GeneDx collaborates with biopharma and researchers to share deidentified patient genomic and phenotypic data for drug discovery, clinical trial acceleration, and research; may receive compensation for data sharing and testing services.
3. Health systems partnerships (Epic Aura): Partnerships with large health systems for integrated precision medicine delivery across networks through Epic Aura EHR integration.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

GeneDx is a clinical genomics laboratory that performs advanced whole exome and whole genome sequencing tests to diagnose rare and inherited diseases, with core products ExomeDx and GenomeDx (including rapid, ultraRapid, prenatal, and trio configurations). All tests are interpreted using the proprietary GeneDx Infinity rare disease dataset and AI-enabled variant classification, with results delivered through a provider portal and Epic Aura EHR integration.

Product overview

GeneDx is a clinical genomics company offering a unified genetic testing platform centered on its massive rare disease dataset, GeneDx Infinity™. The platform is anchored by two core sequencing product families — GenomeDx™ (whole genome sequencing, including Rapid and ultraRapid variants) and ExomeDx™ (whole exome sequencing, including + mito, Rapid, and Prenatal variants) — supported by prenatal testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal), Trio testing (parental co-sampling for improved yield), and Targeted Variant Testing for cascade/familial variant confirmation. All products are accessed through the GeneDx Provider Portal (with Epic Aura EHR integration) and backed by 150+ genetic counselors for pre- and post-test support. Patient access programs (Financial Assistance, Epilepsy Partnership, Autism/SHANK3) and biopharma data services wrap around the testing portfolio. The Infinity™ dataset (2.5M+ tests, ~1M exomes/genomes, 8M+ phenotypic datapoints, 10.5K+ curated gene-disease associations) combined with AI-driven interpretation (originally augmented by the 2025 Fabric Genomics acquisition) powers variant classification across the entire test menu, with reanalysis included for no extra charge on exome/genome tests.

Differentiator

Problem solved

Functional benefit

Brands

• GeneDx Infinity: Largest rare disease dataset platform powered by 2.5+ million genetic tests, nearly 1 million exomes and genomes, and over 8 million phenotypic data points.
• ExomeDx
• GenomeDx

Products and services

• ExomeDx Whole exome sequencing test analyzing protein-coding regions of ~20,000 genes, with sequence variants, copy-number variants, and optional mitochondrial variant detection. Available as proband, duo, or trio with standard results in as soon as 2 weeks. Diagnostic rate 25-35% across indications; 17% greater yield than standard testing.
• GenomeDx Whole genome sequencing test capturing coding, non-coding, intronic, and regulatory variants, CNVs, repeat expansions (10 conditions), mitochondrial variants, and structural variants. Available as proband, duo, or trio with standard results in 4 weeks. Diagnostic rate 40-50% across indications.
• Rapid and ultraRapid Genomic Sequencing Rapid exome delivers provisional results within 7 days; ultraRapid genome delivers results as soon as 2 days for critically ill NICU/PICU and urgent cardiac care patients. Built for time-sensitive clinical scenarios.
• Prenatal Genetic Testing (Prenatal CMA, ExomeDx Prenatal, GenomeDx Prenatal) Prenatal suite including Chromosomal Microarray Analysis (CMA), ExomeDx Prenatal, and GenomeDx Prenatal, with reflex to exome on the same sample. Supports amniotic fluid, CVS, and products of conception. Prenatal CMA diagnostic yield ~13%; prenatal exome 31% incremental yield; prenatal genome 19-36% incremental yield.
• Trio Testing Proband + duo or trio configurations across exome and genome tests, including parental samples for inheritance-based variant interpretation. Trio testing improves diagnostic yield by 7-15% and reduces inconclusive results by over 30% compared to gene panels.
• Targeted Variant Testing Targeted genetic testing of previously identified familial variants for cascade testing, carrier testing, confirmatory testing, and mosaic variant analysis. Results in 2-3 weeks (3-4 weeks for variant confirmation). CLIA-confirmable.
• GeneDx Infinity Proprietary rare disease dataset and AI-driven analytics platform built from 2.5M+ genetic tests, nearly 1M exomes and genomes, 8M+ phenotypic datapoints, and 10.5K+ curated gene-disease associations. Combines AI and clinical expertise to power variant interpretation across the test menu and to support biopharma drug discovery and clinical trial acceleration.
• GeneDx Provider Portal Online provider-facing portal for ordering tests, viewing the test catalog, submitting specimens, accessing results, billing, and managing accounts. Integrated with Epic Aura EHR for in-workflow test ordering and result delivery.
• Epic Aura EHR Integration Native Epic Aura EHR integration enabling providers to place GeneDx test orders directly within their Epic workflow, with streamlined results delivery and clinical decision support across health system networks.
• Biopharma Services B2B offering that leverages the GeneDx Infinity rare disease dataset to accelerate drug discovery, clinical trial enrollment, and biopharma research partnerships through access to deeply phenotyped, deidentified rare disease genomic data.
• Newborn Screening Program Population-scale newborn genetic screening initiative partnering with state programs (e.g., Florida's Sunshine Genetics Program) to expand screening from ~60 conditions to nearly 900 rare genetic diseases using whole genome sequencing.
• Epilepsy Partnership Program Patient access program expanding access to exome sequencing for eligible children with epilepsy, even when insurance coverage is limited.
• Autism Partnership Program / SHANK3 Genetic Testing Patient access solution offering guideline-backed exome testing with financial support for eligible patients meeting eight clinical criteria.
• Financial Assistance Program Program to reduce out-of-pocket costs for patients, complementing Medicaid coverage in 36-37 states and broad in-network commercial coverage. Includes interest-free payment plans for eligible patients and families.
• Genetic Counseling Support Clinical support service from 150+ genetic counselors providing pre-order guidance, mid-process assistance, and post-result interpretation including pre-test patient education and post-test genetic counseling for providers and patients.

Quantifiable outcome

• 60% of diagnosed patients experience a change in medical management
• +9 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered minor, flagship and core.

• Goldman Sachs (Global Healthcare Conference)minorGTM or Marketing Partner · 9 June 2026GeneDx management participated in the Goldman Sachs 47th Annual Global Healthcare Conference (June 8–10, 2026, Miami, FL), including a fireside chat on June 9 featuring CFO Kevin Feeley discussing expansion into pediatric neurology markets.
• Fabric GenomicsflagshipStrategic or Co-development Partner · 1 May 2025AI-driven genomic interpretation company acquired by GeneDx in April/May 2025 for $33.2–$51M (cash upfront of ~$33M with earn-outs). Q1 2026 results revealed $31.2–$31.3M impairment charge (94% write-off), leading to multi-class-action lawsuits.
• Tampa General Hospital / Florida (Sunshine Genetics Newborn Screening Program)flagshipStrategic or Co-development PartnerFive-year Florida pilot program at Tampa General Hospital partnering with GeneDx to expand newborn screening from 60 to nearly 900 rare genetic diseases via whole genome sequencing. Spearheaded by State Rep. Adam Anderson following personal loss of his son to Tay-Sachs; backed by tens of millions in state investment.
• A.J. Anderson Foundation / Florida Institute for Pediatric Rare Diseases at FSUcoreStrategic or Co-development PartnerExpanded partnership co-hosting a rare disease conference in Pinellas County, FL, supporting the Sunshine Genetics Act and newborn whole-genome sequencing pilot program for genetic screening initiatives.
• Ultragenyx (Rare Bootcamp)minorGTM or Marketing PartnerSponsored Ultragenyx's Rare Bootcamp event in Boston in April 2026, a free multi-day forum helping families of children with rare diseases learn about drug development; co-sponsored with Alexion, BioMarin, and BridgeBio.
• Genome MedicalcoreChannel Partner/ Reseller/ DistributorPartner telehealth service enabling patients without local licensed healthcare providers to access GeneDx exome testing through Genome Medical's clinician network.
• Epic (Epic Aura EHR integration)flagshipTechnology or IntegrationEpic Aura EHR integration enables providers to place GeneDx orders directly within their Epic workflow, supporting streamlined ordering and results delivery across health systems.
• Carelon (coverage policy)flagshipStrategic or Co-development PartnerCarelon's new outpatient genome coverage policy cited by Piper Sandler as a potential structural de-risking event, expected to drive approximately $100 in incremental average selling price by the second half of 2027.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Natera: Specialized clinical genetics lab with strong oncology and reproductive health testing; overlaps with GeneDx in prenatal and rare-disease exome/genome testing.
• Fulgent Genetics: Clinical genetics lab offering whole-exome, whole-genome, and panel tests with a similar provider portal and payor-billing model; comparable in pediatric rare-disease positioning.
• Invitae: Clinical genetic testing company offering exome, genome, and panel-based testing with a comparable provider-facing model; direct competitor in rare-disease and pediatric genetic diagnostics.

Broad incumbents

• NeoGenomics: Oncology-focused clinical lab expanding into broader molecular and rare-disease genomics; overlaps in hospital channel and biopharma services.
• Myriad Genetics: Established clinical genetics company with hereditary cancer, pharmacogenomics, and growing rare-disease offerings; broader menu but overlapping provider and payor channels.
• Quest Diagnostics: Largest U.S. clinical lab with broad molecular and genomic testing; entering incoming President Mark Gardner's former employer — directly competitive in exome/genome and payor contracts.
• Labcorp: Major clinical lab with growing genomics and oncology offerings (including OmniSeq acquisition); broad hospital and payor channel that increasingly competes for exome/genome volume.

Emerging players

• Veracyte: Genomic diagnostics company combining proprietary testing with AI-driven analytics; comparable in using growing genomic datasets to power clinical interpretation and biopharma partnerships.
• Tempus AI: AI-driven precision medicine company combining multimodal clinical and genomic data for diagnostics and biopharma; comparable in using AI/large datasets to drive clinical insights.

Others

• Pacific Biosciences: Long-read sequencing technology provider enabling high-accuracy exome/genome workflows; adjacent enabling technology for clinical labs like GeneDx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/gened
• Facebookfacebook.com/GeneDxLab
• LinkedInlinkedin.com/company/genedx

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneDx